Author: Pablos, J. L.; Galindo, M.; Carmona, L.; Retuerto, M.; Lledo, A.; Blanco, R.; Gonzalez-Gay, M. A.; Martinez-Lopez, D.; Castrejon, I.; Alvaro-Gracia, J. M.; Fernandez-Fernandez, D.; Mera-Varela, A.; Manrique-Arija, S.; Mena-Vazquez, N.; Fernandez-Nebro, A.; group, RIER investigators
Title: Clinical Outcomes of Patients with COVID-19 and Chronic Inflammatory and Autoimmune Rheumatic Diseases: A Multicentric Matched-Cohort Study Cord-id: ga56ozp3 Document date: 2020_6_20
ID: ga56ozp3
Snippet: ABSTRACT Background The impact of inflammatory rheumatic diseases on COVID-19 severity is poorly known. Here we compare the outcomes of a cohort of rheumatic patients with a matched control cohort to identify potential risk factors for severe illness. Methods In this comparative cohort study, we identified hospital PCR+ COVID-19 rheumatic patients with chronic inflammatory arthritis (IA) or autoimmune/immunomediated diseases (AI/IMID). Non-rheumatic controls were randomly sampled 1:1, and matche
Document: ABSTRACT Background The impact of inflammatory rheumatic diseases on COVID-19 severity is poorly known. Here we compare the outcomes of a cohort of rheumatic patients with a matched control cohort to identify potential risk factors for severe illness. Methods In this comparative cohort study, we identified hospital PCR+ COVID-19 rheumatic patients with chronic inflammatory arthritis (IA) or autoimmune/immunomediated diseases (AI/IMID). Non-rheumatic controls were randomly sampled 1:1, and matched by age, sex, and PCR date. The main outcome was severe COVID-19, defined as death, invasive ventilation, ICU admission, or serious complications. We assessed the association between the outcome and potential prognostic variables, adjusted by COVID treatment, using logistic regression. Results The cohorts were composed of 456 rheumatic and non-rheumatic patients, in equal numbers. Mean age was 63 [IQR 53-78] and male sex 41% in both cohorts. Rheumatic diseases were IA (60%) and AI/IMID (40%). Most patients (74%) had been hospitalised, and the risk of severe COVID was 31.6% in the rheumatic and 28.1% in the non-rheumatic cohort. Ageing, male sex and previous comorbidity (obesity, diabetes, hypertension, cardiovascular, or lung disease) increased the risk in the rheumatic cohort by bivariate analysis. In logistic regression analysis, independent factors associated with severe COVID were increased age (OR 5.31; CI 3.14-8.95), male sex (2.13; CI 1.35-3.36) and having an AI/IMID (OR 1.98; CI 1.15-3.41). Conclusion In patients with chronic inflammatory rheumatic diseases aging, sex and having an AI/IMID but not IA nor previous immunosuppressive therapies were associated with severe COVID-19.
Search related documents:
Co phrase search for related documents- logistic regression analysis and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- logistic regression analysis and lung disease hypertension: 1, 2, 3
- logistic regression analysis and lung disease hypertension diabetes: 1, 2, 3
- logistic regression analysis and lung disease hypertension diabetes obesity: 1
- logistic regression analysis and lung inflammation: 1, 2, 3
- logistic regression analysis and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- logistic regression and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30
- logistic regression model and lopinavir ritonavir: 1, 2, 3, 4, 5, 6
- logistic regression model and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- logistic regression model and lung disease hypertension: 1, 2, 3, 4
- logistic regression model and lung disease hypertension diabetes: 1, 2
- logistic regression model and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31
- lopinavir ritonavir and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9
- lopinavir ritonavir and lung inflammation: 1, 2, 3, 4, 5, 6, 7, 8
- lopinavir ritonavir and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- lung disease and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- lung disease hypertension and lymphocyte count: 1, 2
- lung disease hypertension diabetes and lymphocyte count: 1
- lung inflammation and lymphocyte count: 1, 2, 3, 4, 5, 6, 7
Co phrase search for related documents, hyperlinks ordered by date